Biocon Limited (BOM:532523)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Biosimilars	104.31B	90.17B	88.24B	55.84B	34.64B
Generics	31.68B	30.18B	27.99B	27.64B	23.41B
Services	37.39B	36.42B	34.89B	31.93B	26.04B
Inter-Segment Revenue	-4.11B	-4.16B	-3.56B	-	-
Unallocated/Elimination	-	-	-	-3.86B	-2.76B
Novel Biologics	-	-	-	192.00M	510.00M
Total	169.27B	152.62B	147.56B	111.74B	81.84B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	9.18B	9.77B	16.08B	16.74B	13.56B
United States of America	79.95B	70.42B	64.55B	41.43B	29.95B
European Union (Including Ireland)	46.17B	38.48B	35.17B	11.78B	-
Rest of The World	33.98B	33.95B	31.76B	41.79B	21.47B
Ireland	-	-	-	-	16.86B
Total	169.27B	152.62B	147.56B	111.74B	81.84B

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 6, 2026

Data Sources Report a data error